[PDF] Top 20 Pharmacological management of type 2 diabetes: what's new in 2017?

... this pharmacological class has still a place in the various algorithms proposed for the management of hyperglycemia in ...benefit of hindsight, the results of the ... Voir le document complet

... the Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, Rockville, ...comments of Drs. Scheen (1) and Buchanan (2) regarding our article (3), which ... Voir le document complet

... open new perspectives for the management of ...both in a glucose-dependent manner, these agents are characterized by a mechanism of action that is distinct from (and also complementary ... Voir le document complet

... failure of dual oral therapy or even as add-on to insulin for a majority of patients with ...differ in the extent to which it lowers the glucose ...reduction in fasting plasma glucose ... Voir le document complet

... Most of these trials were rather short-term (12-24 weeks) so that it is difficult to conclude on the long-term efficacy of each ...Durability of the glucose-lowering effect is a crucial issue because ... Voir le document complet

... comparison of agents within a pharmacologic class or between drug classes is hazardous, as renal outcomes are inconsistently defined across ...impact of many specific drugs on renal outcome measures ... Voir le document complet

... number of strengths including size (high statistical power even after risk factor stratification), prospective design (reducing the risk of reverse causation bias), and inclusion of well ... Voir le document complet

... resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 ...safety of dulaglutide added onto pioglitazone and metformin ... Voir le document complet

... l’exon 2 jusqu’à l’exon 4 du gène a provoqué une augmentation d’un facteur 2,8 des taux protéiques de LDLR favorisant une clairance des lipoprotéines à Apo B cinq fois plus efficace comparée aux souris sauvages ... Voir le document complet

... measurement of AGE and it may be influenced by other fluorophores in the skin; neverthe- less, SAF does correlate with pentosidine, a common AGE, in skin ...with type 2 diabetes, ... Voir le document complet

... relation in patients with type 2 ...results of earlier studies, an epidemiological study cannot show a causal relation, and such an observational database does not provide the detailed ... Voir le document complet

... studies in patients with various degrees of HI and their hepatic safety was carefully analyzed in large clinical ...changes in PK characteristics of DPP-4 inhibitors were observed ... Voir le document complet

... Benoît Viollet, Louise Lantier, Jocelyne Devin-Leclerc, Sophie Hébrard, Chloé Amouyal, et al... Tar- geting the AMPK pathway for the treatment of Type 2 diabetes...[r] ... Voir le document complet

... 8% of diabetic patients in the treated group had no increased need for medication during the course of the ...that, in their initial studies, 100,000 IU of D2 improved endothelial ... Voir le document complet

... response of the infected host, ...infection of the thymus (Fig. 1) A novel type of mechanism was recently identi- fied and might intervene in intimate conjunction with a bystander ... Voir le document complet

... definition of standard care in T2D, restricted to the control of hyperglycaemia, is also challenging, especially given the commercialization of an increasing number of ... Voir le document complet

... form of B cell deficiency) who developed type 1 diabetes ’ despite complete absence of B cells and antibodies ( 76 ...contribution of aAbs could consist in skewing Ag ... Voir le document complet

... Gaal 2 1 Division of Diabetes, Nutrition, and Metabolic Disorders, Department of Medicine, CHU Sart Tilman (B35), University of Liège, B-4000 Liège, Belgium 2 Department ... Voir le document complet

... blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists) or various cardioprotective medications (among which ...risk of the population, but also ... Voir le document complet

... in our muscle samples, which excludes potential contam- ination via adipocyte infiltration (data not ...shown). In line with a lower HSL protein content, muscle DAGH activity, presumably for a large part ... Voir le document complet